Many mechanisms have been proposed for the positive effects of monoclonal antibodies in cancer therapy. New data indicate that both the variable, antigen-binding region of an antibody and the Fc region are capable of influencing anti-cancer immunity (pages 443–446).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
British Journal of Cancer Open Access 12 December 2003
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kohler, G. & Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256, 495–497 (1975).
Clynes, R.A., Towers, T.L., Persta, L.G., & Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nature Med. 6, 443– 446 (2000).
Masui, H. et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res. 44, 1002–1007 (1984).
Drebin, J.A., Link, V.C., Stern, D.F., Weinberg, R.A. & Greene, M.I. Downregulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41, 697–706 ( 1985).
Waldmann, T.A. The multichain interleukin-2 receptor: from the gene to the bedside. Harvey Lect. 82, 1–17 ( 1986).
Dinney, C.P. et al. Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide. Clin. Cancer Res. 3, 161–168 (1997).
Park, B.W. et al. Rationally designed anti-HER2/neu peptide mimetic disables P185HER2/ neu tyrosine kinases in vitro and in vivo. Nature Biotechnol. 18, 194–198 (2000).
Vuist, W.M. et al. Lymphoma regression induced by monoclonal anti-idiotypic antibodies correlates with their ability to induce Ig signal transduction and is not prevented by tumor expression of high levels of Bcl-2 protein. Blood 83, 899–906 ( 1994).
Vadhan-Raj, S. et al. Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites . J. Clin. Oncol. 6, 1636– 1648 (1988).
Clynes, R., Takechi, Y., Moroi, Y., Houghton, A., & Ravetch, J.V. Fc receptors are required in passive and active immunity to melanoma. Proc. Natl. Acad. Sci. USA 95, 652–656 (1998).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Houghton, A., Scheinberg, D. Monoclonal antibody therapies–a ‘constant’ threat to cancer. Nat Med 6, 373–374 (2000). https://doi.org/10.1038/74621
Issue Date:
DOI: https://doi.org/10.1038/74621
This article is cited by
-
Immunological ignorance of solid tumors
Springer Seminars in Immunopathology (2005)
-
Monoklonale Antikörper
Der Onkologe (2005)
-
Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies
Cancer and Metastasis Reviews (2005)
-
Phase I clinical trial of the bispecific antibody MDX-H210 (anti-FcγRI × anti-HER-2/neu) in combination with Filgrastim (G-CSF) for treatment of advanced breast cancer
British Journal of Cancer (2003)
-
Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade
Nature Medicine (2003)
